Review anchor
Peroxisome proliferator-activated receptor delta
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
Evidence Snapshot
Peroxisome proliferator-activated receptor delta
CHEMBL2458
SINGLE PROTEIN
Mus musculus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor delta as ChEMBL target CHEMBL2458, mapped to UniProt P35396. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2458
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35396
Peroxisome proliferator-activated receptor delta
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Peroxisome proliferator-activated receptor delta matters
Peroxisome proliferator-activated receptor delta is reviewed as Peroxisome proliferator-activated receptor delta (UniProt P35396); the current evidence base includes 0 approved drugs, 247 compounds, and 95 assays, with lead potency reaching pChEMBL 8.6.
Protein context
Peroxisome proliferator-activated receptor delta
Peroxisome proliferator-activated receptor delta Sequence length is 440 aa.
Review this target as Peroxisome proliferator-activated receptor delta, mapped to UniProt P35396. Sequence length is 440 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35396
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 247 compounds, and 95 assays for this target. The dominant activity type is EC50. CHEMBL1169827 is the current potency anchor at pChEMBL 8.6.
Use CHEMBL1169827 as the tractability anchor when discussing potency (pChEMBL 8.6).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 8.6
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor delta matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35396, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
247
Total Compounds
95
Total Assays
0
Approved Drugs
IC50: 11.0, EC50: 177.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1169827
|
8.6 | EC50 | — |
|
|
No preferred name
CHEMBL1075894
|
8.3 | EC50 | — |
|
|
No preferred name
CHEMBL5267473
|
8.2 | EC50 | — |
|
|
No preferred name
CHEMBL5272996
|
8.2 | EC50 | — |
|
|
No preferred name
CHEMBL5283926
|
8.2 | EC50 | — |
Source Header